Table 3.

Summary of phase II trials of epidermal growth factor receptor inhibitors

						Results (%)*
Reference	Phase	Disease stage	Test drug	Single/combination	Cohort size	pCR rate	cCR rate	Other endpoints	Toxicity
66	II	T3–4 N–/+	Panitumumab	Single	19	0	–	Downstaging 41 Negative CRM 76 LRC 90 DFS 79	GI disturbance 89 Grade 4 toxicity 21
67	II	T3–4 N–/+	Cetuximab	Cetuximab + capecitabine	31	0	–	Downstaging 42	GI disturbance 13 Grade 4 toxicity 3
68	II	T3–4 N–/+	Panitumumab	Panitumumab + oxaliplatin +5‐FU	60	21	–	Downstaging 58	GI disturbance 39 1 death
69	II	T3–4 N–/+	Panitumumab	Panitumumab + capecitabine versus capecitabine alone	68	10 (18)	–	R0 resection 85 (93) Sphincter salvage 69 (70) Downstaging 87 (85)	GI disturbance 10 (4)
70	II	T3–4	Cetuximab	Cetuximab + capecitabine + oxaliplatin versus capecitabine + oxaliplatin	165	11 (9)	11 (7)	Radiological response 71 (51)	GI disturbance 8 (9)
71	II	T2–4 N–/+	Cetuximab	Cetuximab + capecitabine + irinotecin	82	17	5	R0 resection 82	GI disturbance 25 Grade 4 toxicity 10
72	II	T3–4 N–/+	Cetuximab	Cetuximab + capecitabine	47	8	–	3‐year DFS 72 3‐year RFS 74 3‐year OS 68	2 of 32 unable to complete treatment owing to GI disturbance and leucopenia
73	I–II	T3–4 N–/+	Cetuximab	Cetuximab + capecitabine + oxaliplatin	60	8	–	5‐year OS 76 3‐year DFS 88 5 ‐year CSS 78	Grade 2 toxicity 5

^*Results for control group are shown in parentheses. pCR, pathological complete response; cCR, clinical complete response; CRM, circumferential resection margin; LRC, locoregional control; DFS, disease‐free survival; GI, gastrointestinal; 5‐FU, 5‐fluorouracil; RFS, relapse‐free survival; OS, overall survival; CSS, cancer‐specific survival.